Eli Lilly-NCCD deal to advance understanding of Type 2 diabetes & CVD
Category: #health  By Dhananjay Punekar  Date: 2018-04-30
  • share
  • Twitter
  • Facebook
  • LinkedIn

Eli Lilly-NCCD deal to advance understanding of Type 2 diabetes & CVD

Eli Lilly and Company, the globally renowned pharma titan, has scarcely announced a strategic collaboration with the National Center for Cardiovascular Diseases in China. Incidentally, this move has come on the heels of the fact that China has now emerged as a potential investment hub for U.S. pharma and biotech firms.

Sources claim that Eli Lilly’s collaboration with NCCD takes root amidst a scenario where the regional healthcare industry is expected to advance appreciably. As per experts, China healthcare industry is likely to witness an exponential growth graph with an escalated revenue projection by the end of the year 2022. The partnership will be focusing on advancing the scientific understanding of Type 2 diabetes and the complications that may stem from the same, such as cardiovascular disease (CVD).

The association is likely to help in improving the healthcare infrastructure & facilities for the diabetics in the country. Both the firms will apparently develop a CVD risk calculator to enhance screening & help in the effective management of diabetes at the initial stage. It has been forecast that the combined entity will carry out joint research to determine new biomarkers for CVD, DKD, and diabetes progression.

NCCD and Eli Lilly will be authorized to access data from over one million of the Chinese populace suffering from Type 2 diabetes and prone to increased CVD risk.

Reportedly, since the last thirty years, there has been a rise in the diabetic population in China. It has increased from 1% in 1980 to approximately 11% in 2017. However, less than 33% of Chinese population suffering from diabetes receive medical treatment. Analysts project that partnership between the two reputed organizations will help the country in effectively treating diabetes through new drug combinations, thereby enhancing the lifespan as well as quality of life of patients afflicted with the silent killer.



About Author

Dhananjay Punekar

Email: [email protected]   

Dhananjay Punekar

Dhananjay Punekar presently develops content for a slew of portals, including Market Size Forecasters and Algosonline. A post graduate in mathematics and business administration, he worked in Infosys BPO Limited prior to switching his professional genre. As a content wr...

Read More

More News By Dhananjay Punekar

AstraZeneca gets import & marketing approval for Durvalumab in India
AstraZeneca gets import & marketing approval for Durvalumab in India
By Dhananjay Punekar

AstraZeneca Pharma India, a division of pharma & biopharma giant AstraZeneca plc, has received a green signal from the Indian drug regulating agency DCGI (Drug Controller General of India) for its drug Durvalumab c...

BP exits deal with Woolworths, retail firm looks out for alternatives
BP exits deal with Woolworths, retail firm looks out for alternatives
By Dhananjay Punekar

BP Plc, a UK based oil & gas firm, has decided to terminate its USD 1.8 billion acquisition deal with Australian retail giant Woolworths. For the record, the British oil & gas company had signed a pact to purch...

Sarepta obtains positive results on DMD therapy, shares skyrocket 50%
Sarepta obtains positive results on DMD therapy, shares skyrocket 50%
By Dhananjay Punekar

The shares of Sarepta Therapeutics Inc., a medical research & drug development firm, climbed up by 50% after the firm released initial results derived from clinical treatment on patients suffering from Duchenne mus...